Posts Tagged: "Gene Quinn"

Webinar: Can the PTAB Be Fixed? Three Perspectives on Institution Practices – Sponsored by Innovation Alliance

A centerpiece of the America Invents Act (AIA) was the creation of a new quasi-judicial administrative body — the Patent Trial and Appeal Board (PTAB) — to adjudicate patent disputes. The drafters of the AIA intended the PTAB to be a cheaper and faster alternative to district court litigation. They thought that in providing that alternative, the PTAB would encourage…

Tillis Addresses Criticism of His Eligibility Reform Bill, Warns WD of TX Not to Backtrack on Standing Order

Senator Thom Tillis (R-NC) has been perhaps the most active and passionate Congress person when it comes to intellectual property (IP) rights, and patents specifically, in recent history. In early August, he released the first draft of the Patent Eligibility Restoration Act of 2022, which if enacted would abrogate the Supreme Court’s decisions in Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S.Ct. 2107 (2013) and Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S.Ct. 1289 (2012). He has also been closely involved with oversight of the U.S. Patent and Trademark Office (USPTO) on topics such as patent quality and has written numerous letters to the Biden Administration on issues including the waiver of IP obligations under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, the theft of U.S. IP by Chinese companies, and more. While he seemed fairly exasperated by the end of his last attempt at eligibility reform in 2019, he explains below that the Supreme Court’s refusal to fix the problem by denying the American Axle case inspired him to revive his efforts.

Webinar: How to Navigate the Risks of SEP Licensing and SEP Litigation – Sponsored by IPlytics

Connectivity technology will not only connect smartphones, tablets, and computers but every device or object across many industry verticals linking other vehicles, trucks, traffic lights, machines, TVs, smart meters, or medical devices. Technology standards such as 4G, 5G, Wi-Fi, HEVC, VVC, and many more will enable connectivity that heavily relies on standards subject to standard essential patents (SEPs). SEP-related global…

Dissent Today, Majority Tomorrow—A Federal Circuit Approach to Rehearing

Talk about snatching victory from the jaws of defeat! That is precisely what the Federal Circuit did for HEC Pharm Co. recently in Novartis Pharmaceuticals Corp. v. Accord Healthcare Inc. et al (No. 2021-1070). In what can only be characterized as an astonishingly unprecedented procedural betrayal of justice, Novartis recently found itself on the losing side of a request for panel rehearing. Save for a moment just how extraordinarily uncommon it is for the Federal Circuit to grant panel rehearing, and likewise save for a moment how extremely uncommon it is for the Federal Circuit to overrule a prior panel decision even when a panel rehearing is granted. But in Novartis Pharmaceuticals v. Accord Healthcare, neither of the panel members in the majority of the original opinion even agreed to rehear the case, let alone agreed to reverse their prior ruling.

Webinar: Outperforming Your Peers (Part 2) – Sponsored by LexisNexis

After a very successful first panel discussion focused on innovation, Gene Quinn sits down once again with in-house lawyers from some of the most innovative companies in the world to speak about their company’s vision on innovation. The panelists were chosen from companies identified in the “Innovation Momentum 2022: The Global Top 100” report that was published by LexisNexis Intellectual…